A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Saved in:
Bibliographic Details
Published inCancer cell Vol. 35; no. 6; pp. 948 - 949
Main Authors Li, John Y., Perry, Samuel R., Muniz-Medina, Vanessa, Wang, Xinzhong, Wetzel, Leslie K., Rebelatto, Marlon C., Masson Hinrichs, Mary Jane, Bezabeh, Binyam Z., Fleming, Ryan L., Dimasi, Nazzareno, Feng, Hui, Toader, Dorin, Yuan, Andy Q., Xu, Lan, Lin, Jia, Gao, Changshou, Wu, Herren, Dixit, Rakesh, Osbourn, Jane K., Coats, Steven R.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 10.06.2019
Online AccessGet full text

Cover

More Information
Bibliography:erratum
ObjectType-Correction/Retraction-1
content type line 23
SourceType-Scholarly Journals-1
ISSN:1535-6108
1878-3686
1878-3686
DOI:10.1016/j.ccell.2019.05.010